A Randomized, Open-label Study of Ponatinib Versus Nilotinib in Patients With Chronic Myeloid Leukemia in Chronic Phase Following Resistance to Imatinib
Phase of Trial: Phase III
Latest Information Update: 02 Nov 2017
At a glance
- Drugs Ponatinib (Primary) ; Nilotinib
- Indications Chronic myeloid leukaemia
- Focus Registrational; Therapeutic Use
- Acronyms OPTIC-2L
- Sponsors ARIAD Pharmaceuticals
- 02 Nov 2017 This study has been discontinued in Denmark, according to European Clinical Trials Database record.
- 28 Oct 2017 This study has been completed in Spain, according to European Clinical Trials Database record.
- 10 Jun 2017 Biomarkers information updated